Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Publié en janvier 2019 LANCET

REDUCTION OF SERUM IL17F AND IL22 BY IL23P19 BLOCKADE WITH GUSELKUMAB IS ASSOCIATED WITH IMPROVEMENT IN JOINT SYMPTOMS IN PSORIATIC ARTHRITIS

Publication précédente

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Publication suivante